Trial · NCT00385515
Efficacy of SNX-1012 in the Treatment of Oral Mucositis
NCT00385515, Phase 2, Completed, Mucosal Therapeutics; results first posted 2009-03-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of SNX-1012 in the Treatment of Oral Mucositis. Trials, record NCT00385515. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00385515
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of SNX-1012 in the Treatment of Oral Mucositis
- NCT number
- NCT00385515
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 81 participants, actual
- Lead sponsor
- Mucosal Therapeutics
- Conditions
- Stomatitis, Oral Mucositis
- Interventions
- SNX-1012 (meclocycline sulfosalicylate), placebo
- First posted
- 2006-10-09
- Last updated
- 2009-05-07
- Results first posted
- 2009-03-18
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of Ulcerative Oral Mucositis | At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle | All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to document the duration for those that developed recurrent ulcerative oral mucositis |
| Secondary | Number of Participants With Ulcerative Oral Mucositis | At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle | All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to identify recurrence of ulcerative oral mucositis. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Duration of Ulcerative Oral Mucositis | At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle | Analysis only includes subjects randomized to the 30mg dose of SNX-1012 | Days | MEAN |
| SECONDARY | Number of Participants With Ulcerative Oral Mucositis | At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Ulcerative Oral Mucositis | SNX-1012 | 2.3 | Standard Deviation 3.04 | Days | |
| Duration of Ulcerative Oral Mucositis | Placebo | 3.2 | Standard Deviation 4.68 | Days | |
| Number of Participants With Ulcerative Oral Mucositis | SNX-1012 | 22 | Participants | ||
| Number of Participants With Ulcerative Oral Mucositis | Placebo | 11 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | SNX-1012 | 57 | |
| Overall Study | STARTED | Placebo | 24 | |
| Overall Study | COMPLETED | SNX-1012 | 53 | |
| Overall Study | COMPLETED | Placebo | 21 | |
| Overall Study | NOT COMPLETED | SNX-1012 | 4 | |
| Overall Study | NOT COMPLETED | Placebo | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| SNX-1012 vs Placebo: Number of Participants With Ulcerative Oral Mucositis |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00385515
GET https://conductscience.org/api/trials/v1/NCT00385515/registered